JP2014511856A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511856A5
JP2014511856A5 JP2014503228A JP2014503228A JP2014511856A5 JP 2014511856 A5 JP2014511856 A5 JP 2014511856A5 JP 2014503228 A JP2014503228 A JP 2014503228A JP 2014503228 A JP2014503228 A JP 2014503228A JP 2014511856 A5 JP2014511856 A5 JP 2014511856A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
human
hiv
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014503228A
Other languages
English (en)
Japanese (ja)
Other versions
JP6054370B2 (ja
JP2014511856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/000857 external-priority patent/WO2012137071A2/en
Publication of JP2014511856A publication Critical patent/JP2014511856A/ja
Publication of JP2014511856A5 publication Critical patent/JP2014511856A5/ja
Application granted granted Critical
Publication of JP6054370B2 publication Critical patent/JP6054370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014503228A 2011-04-06 2012-04-06 ヒトにおけるhiv疾患を予防するおよび/または治療するための医薬組成物 Expired - Fee Related JP6054370B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/072481 2011-04-06
CNPCT/CN2011/072481 2011-04-06
US201161534088P 2011-09-13 2011-09-13
US61/534,088 2011-09-13
CNPCT/CN2012/070761 2012-01-30
CNPCT/CN2012/070761 2012-01-30
US201261609051P 2012-03-09 2012-03-09
US61/609,051 2012-03-09
PCT/IB2012/000857 WO2012137071A2 (en) 2011-04-06 2012-04-06 Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Publications (3)

Publication Number Publication Date
JP2014511856A JP2014511856A (ja) 2014-05-19
JP2014511856A5 true JP2014511856A5 (https=) 2014-09-25
JP6054370B2 JP6054370B2 (ja) 2016-12-27

Family

ID=46969619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503228A Expired - Fee Related JP6054370B2 (ja) 2011-04-06 2012-04-06 ヒトにおけるhiv疾患を予防するおよび/または治療するための医薬組成物

Country Status (20)

Country Link
US (1) US9839684B2 (https=)
EP (3) EP2694101B1 (https=)
JP (1) JP6054370B2 (https=)
KR (1) KR101814857B1 (https=)
CN (1) CN105709221B (https=)
AP (1) AP2013007166A0 (https=)
AU (1) AU2012238351B2 (https=)
BR (1) BR112013025481B8 (https=)
CA (1) CA2832022C (https=)
CL (1) CL2013002836A1 (https=)
DK (1) DK2694101T3 (https=)
ES (1) ES2606511T3 (https=)
IL (1) IL228666A (https=)
MX (1) MX343037B (https=)
PH (1) PH12013502064A1 (https=)
PL (1) PL2694101T3 (https=)
PT (1) PT2694101T (https=)
RU (1) RU2609769C2 (https=)
SG (1) SG194079A1 (https=)
WO (1) WO2012137071A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US10857223B2 (en) * 2014-06-10 2020-12-08 Case Western Reserve University Autologous and allogenic HIV-1 proteins for the treatment of latent HIV-1 infection
ES2876036T3 (es) * 2015-01-30 2021-11-11 Univ Tokyo Composición que contiene una bacteria láctica, composición farmacéutica oral para su uso en el tratamiento de infecciones por VPH y/o tumores asociados a VPH y agente inductor de inmunidad de la mucosa para su uso en dotar de inmunidad mucosal contra la infección por VPH
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
WO2020188111A1 (en) * 2019-03-21 2020-09-24 21C Bio Vaccine to pathogenic immune activation cells during infections
EP4088729B1 (en) * 2020-01-10 2025-11-12 Immunobiome Inc. Novel lactobacillus plantarum strain, polysaccharides derived from strain, and use thereof
US20220241400A1 (en) * 2021-02-02 2022-08-04 Provaxus, Inc. Immunomodulation platform and methods of use

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82104A0 (en) 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
JPS6485072A (en) 1987-09-25 1989-03-30 Nat Inst Health Recombinant vaccinia virus
JPH01148183A (ja) 1987-12-04 1989-06-09 Hiroshi Shibuta 組み換えワクチニアウイルス
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥hivプロウイルス、細胞系及びその使用
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
EP0502105A4 (en) 1989-11-20 1993-02-24 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
AU672581B2 (en) 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
DK0538496T3 (da) 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
DE4141741A1 (de) 1991-12-13 1993-06-17 Gisela Kielmann Verfahren zur bekaempfung des human imune deficiency virus
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6136318A (en) 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
WO1995007099A1 (en) 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccine and process for producing the same
JPH07170982A (ja) 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
EP0832197A4 (en) 1995-06-07 2002-10-16 Syntro Corp RECOMBINANT AVIAN SMALLPOX VIRUS AND USES THEREOF
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JPH1085072A (ja) 1996-09-13 1998-04-07 Kichinosuke Takemaru 家具転倒防止器具
US6001155A (en) 1997-03-17 1999-12-14 Pease; John R. Polyphasic pressurized homogenizer
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US5895758A (en) * 1997-06-10 1999-04-20 Bio-Energy Systems Strain of lactobacillus Plantarum
CA2293826A1 (en) 1997-06-11 1998-12-17 Brigitte Gicquel Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
JP3899165B2 (ja) 1997-08-06 2007-03-28 ビー・エル・オートテック株式会社 ロボットアームの過負荷保護装置
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US7189402B1 (en) 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
EP1084709A1 (en) 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
CA2387921A1 (en) 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク エンド カムパニー インコーポレーテッド コドン最適化hiv1−gag、pol、nefおよび修飾体を発現する増強された第1世代アデノウイルスワクチン
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
WO2002031168A2 (en) 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
GB0030857D0 (en) 2000-12-18 2001-01-31 Medical Res Council Therapeutic compositions
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
JP4554887B2 (ja) 2001-03-08 2010-09-29 アメリカ合衆国 改変HIVエンベロープ、gag、およびpol遺伝子を発現するMVA
WO2002102409A1 (en) 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
AU2002332736A1 (en) 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
US20070077257A1 (en) 2001-09-14 2007-04-05 Emini Emilio A Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
DE60226175T2 (de) 2001-11-14 2009-07-09 Novavax, Inc. Mycobakterieller impfstoff
US20030133912A1 (en) 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
AU2003210688A1 (en) 2002-01-31 2003-09-02 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
JP4343708B2 (ja) 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ.エヌ.エス.ウ.エール.エム. 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
JP2003321391A (ja) 2002-04-30 2003-11-11 Japan Science & Technology Corp 組換えワクシニアウイルスを用いたhivワクチン
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CA2487895A1 (en) * 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
CN1490056A (zh) 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP2363143A3 (en) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
JP2007518460A (ja) 2003-05-09 2007-07-12 イントラヴァック インコーポレーテッド 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル
US20100189747A1 (en) 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
MXPA06001996A (es) * 2003-08-28 2006-06-20 Immune Response Corp Inc Composiciones de hiv inmunogeneticas y metodos relacionados.
JP2007037402A (ja) 2003-11-28 2007-02-15 Primmune:Kk 抗ヒト免疫不全ウイルス感染防御用キメラ5型/35型アデノウイルスベクター
WO2005111205A1 (en) 2004-05-18 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
WO2005121378A2 (en) * 2004-06-03 2005-12-22 Saint Louis University Methods and compositions for vaccination
WO2006012320A1 (en) 2004-06-25 2006-02-02 Dow Agrosciences Llc Process for the preparation of 4-trifluoromethyl-2(1h)-pyridinone
US9453239B2 (en) 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
CN101056977B (zh) * 2004-10-04 2013-01-30 拜欧瓦克西姆有限公司 用于治疗hiv感染患者的亚型匹配的灭活全病毒疫苗
EP1856143A2 (en) 2005-02-24 2007-11-21 Medical Research Council Hivcon: anhiv immunogen and uses thereof
AR053275A1 (es) 2005-05-12 2007-04-25 Glaxo Group Ltd Composicion de vacuna
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
AU2008240181B2 (en) 2007-04-12 2014-01-09 Jason Fisher Tuberculosis vaccine and method of using same
WO2009093900A1 (en) 2008-01-25 2009-07-30 Stichting Top Institute Food And Nutrition Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject

Similar Documents

Publication Publication Date Title
JP2014511856A5 (https=)
Volpatti et al. Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity
Banzhoff et al. MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
Riedl et al. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
RU2013147745A (ru) Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
Ai et al. Enhanced protection against pulmonary mycobacterial challenge by chitosan‐formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma‐interferon+ T cell responses
Keijzer et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
Heng et al. Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice
Bivas-Benita et al. Airway CD8+ T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity
Dong et al. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
Flórido et al. Epitope‐specific CD4+, but not CD8+, T‐cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection
WO2013104995A3 (en) Compositions and methods for treating viral infections
Bhide et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization
WO2011091319A3 (en) Dendritic cell vaccines
Belyakov et al. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development
JP2013515490A5 (https=)
CN107708730A (zh) 针对猪流感病毒的基于纳米粒子的疫苗策略
Karuturi et al. Encapsulation of an EP67-conjugated CTL peptide vaccine in nanoscale biodegradable particles increases the efficacy of respiratory immunization and affects the magnitude and memory subsets of vaccine-generated mucosal and systemic CD8+ T cells in a diameter-dependent manner
Carpenter et al. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu
Grover et al. Heat killed Saccharomyces cerevisiae as an adjuvant for the induction of vaccine-mediated immunity against infection with Mycobacterium tuberculosis
Banerjee et al. A comprehensive investigation regarding the differentiation of the procurable COVID-19 vaccines
Rezk et al. Harnessing the Potential of mRNA Vaccines Against Infectious Diseases
JP2013516469A5 (https=)